Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
September 12 2024 - 6:00AM
Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage
biotechnology company advancing novel biologics with potential for
differentiated efficacy and dosing in the largest inflammatory and
immunology (I&I) markets, including for the treatment of atopic
dermatitis (AD), asthma, chronic obstructive pulmonary disease
(COPD) and other I&I indications, today announced that members
of management, will participate in a fireside chat at the Stifel
2024 Immunology and Inflammation Summit on Wednesday, September 18,
2024 at 12:30 p.m. E.T. / 9:30 a.m. P.T.
A live and archived webcast of the fireside chat
and presentation will be available via the News & Events page
in the Investors section of the Apogee Therapeutics website.
About Apogee
Apogee Therapeutics is a clinical-stage
biotechnology company advancing novel biologics with potential for
differentiated efficacy and dosing in the largest inflammatory and
immunology (I&I) markets, including for the treatment of atopic
dermatitis (AD), asthma, chronic obstructive pulmonary disease
(COPD) and other I&I indications. Apogee’s antibody programs
are designed to overcome limitations of existing therapies by
targeting well-established mechanisms of action and incorporating
advanced antibody engineering to optimize half-life and other
properties. APG777, the company’s most advanced program, is being
initially developed for the treatment of AD, which is the largest
and one of the least penetrated I&I markets. With four
validated targets in its portfolio, Apogee is seeking to achieve
best in class efficacy and dosing through monotherapies and
combinations of its novel antibodies. Based on a broad pipeline and
depth of expertise, the company believes it can deliver value and
meaningful benefit to patients underserved by today’s standard of
care. For more information, please
visit www.apogeetherapeutics.com.
Investor Contact:Noel KurdiVP, Investor
Relations Apogee Therapeutics,
Inc.noel.kurdi@apogeetherapeutics.com
Media Contact:Dan Budwick 1AB
dan@1abmedia.com
Apogee Therapeutics (NASDAQ:APGE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Apogee Therapeutics (NASDAQ:APGE)
Historical Stock Chart
From Sep 2023 to Sep 2024